FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to oncology, and can be used to treating cancer in humans. To this end, a therapeutically effective amount of a compound of 2-acetyl-4H,9H-naptho[2,3-b]furan-4,9-dione is administered to the patient, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, or a pharmaceutical composition comprising the same. Administration provides a concentration of the compound in the blood in the subject of at least 0.5 mcm and above for at least 2 hours but less than 24 hours. Group of inventions results in significantly improved antitumor activity of the particles of the napthofuran compound in the pharmaceutical composition due to particle size, high bioavailability and selective antitumor activity.
EFFECT: group of inventions results in a significantly improved antitumor activity of the particles of the napthofuran compound in the pharmaceutical composition due to particle size, high bioavailability and selective antitumor activity.
33 cl, 25 dwg, 16 ex, 15 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL METHODS FOR TARGETING CANCER STEM CELLS | 2011 |
|
RU2591823C2 |
| NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING AT MALIGNANT STEM CELLS | 2011 |
|
RU2571661C2 |
| PURIFIED PYRROLOQUINOLINYL-PYRROLIDINE-2,5-DIONE COMPOSITIONS AND METHODS OF OBTAINING AND APPLICATION THEREOF | 2010 |
|
RU2556205C2 |
| TOPOTECAN MONOHYDROCHLORIDE PENTAHYDRATE IN CRYSTALLINE FORM, CORRESPONDING COMPOSITIONS BASED ON THEM, PREPARATION AND/OR TREATMENT METHODS | 2004 |
|
RU2352572C2 |
| SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USE | 2012 |
|
RU2611007C2 |
| PYRIDO[1,2-A]PYRIMIDONE ANALOG, ITS CRYSTAL FORM, ITS INTERMEDIATE COMPOUND AND METHOD FOR THEIR PREPARATION | 2016 |
|
RU2753696C2 |
| SALTS AND POLYMORPHIC MODIFICATIONS OF THE INHIBITOR VEGF-R | 2006 |
|
RU2369607C1 |
| QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
| CRYSTALLINE FORM OF MALEATE OF CONDENSED PYRIDINE DERIVATIVE AND METHODS FOR USE THEREOF | 2016 |
|
RU2712280C2 |
| CRYSTALLINE AND SALT FORMS OF THE TGF-βR1 INHIBITOR AND THE METHOD OF OBTAINING THEM | 2018 |
|
RU2750702C1 |
